LAUSR

Objectives To assess whether insulin therapy impacts the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of diabetic macular edema (DME) in type 2 diabetes mellitus. Methods This was a retrospective multi-center analysis. The best-corrected visual acuity (BCVA) at 12 months, BCVA change, central macular thickness (CMT), CMT change, and cumulative injection number were compared between the insulin and the oral hypoglycemic agent (OHA) groups. Results The mean final BCVA and CMT improved in both the insulin ( N  = 137; p  < 0.001; p  < 0.001, respectively) and the OHA group ( N  = 61; p  = 0.199; p  < 0.001, respectively). The two treatment groups were comparable for final BCVA ( p  = 0.263), BCVA change ( p  = 0.184), final CMT ( p  = 0.741), CMT change ( p  = 0.458), and the cumulative injections received ( p  = 0.594). The results were comparable between the two groups when stratified by baseline vision ( p  > 0.05) and baseline HbA1c ( p  > 0.05). Conclusion Insulin therapy does not alter treatment outcomes for anti-VEGF therapy in DME.